Premium
Translational aspects of blood–brain barrier transport and central nervous system effects of drugs: From discovery to patients
Author(s) -
de Lange ECM,
HammarlundUdenaes M
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.76
Subject(s) - limiting , blood–brain barrier , drug discovery , pharmacodynamics , pharmacokinetics , central nervous system , medicine , pharmacology , drug , neuroscience , translational research , intensive care medicine , bioinformatics , biology , pathology , mechanical engineering , engineering
The development of CNS drugs is associated with high failure rates. It is postulated that too much focus has been put on BBB permeability and too little on understanding BBB transport, which is the main limiting factor in drug delivery to the brain. An integrated approach to collecting, understanding, and handling pharmacokinetic‐pharmacodynamic information from early discovery stages to the clinic is therefore recommended in order to improve translation to human drug treatment.